Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 7, 2005, Pages 627-633

  Wani, S ^a   Sampliner, R E ^b   Weston, A P ^a   Mathur, S ^a   Hall, M ^a   Higbee, A ^a   Sharma, P ^b,c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; ESOPHAGUS PH; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIATUS HERNIA; HUMAN; HUMAN TISSUE; MALE; PH MEASUREMENT; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; BENZIMIDAZOLES; ESOPHAGEAL PH MONITORING; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS;

EID: 26244458223     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02626.x     Document Type: Article

References (33)

1. Sampliner RE. Practice parameters committee of the ACG. Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97: 1888-95.
2. Fitzgerald RC, Triadafilopoulus G. Recent developments in the molecular characterization of Barrett's esophagus. Dig Dis Sci 1998; 16: 63-80.
3. Haggit RC. Barrett's esophagus, dysplasia and adenocarcinoma. Hum Pathol 1994; 25: 982-93.
4. Reid BJ. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin N Am 1991; 20: 817-34.
5. Bremmer RM, Crookes PF, DeMeester TR, et al. Concentration of refluxed acid and esophageal mucosal injury. Am J Surg 1992; 164: 522-7.
6. Stein HJ, Hoeft S, DeMeester TR. Functional foregut abnormalities in Barrett's esophagus. J Thorac Cardiovasc Surg 1993; 105: 107-11.
7. Iascone C, DeMeester TR, Little AG, et al. Functional assessment, proposed pathogenesis and surgical therapy. Arch Surg 1983; 118: 543-49.
8. Parrilla P, Ortiz A, Martinez DE, et al. Evaluation of the magnitude of gastroesophageal reflux in Barrett's esophagus. Gut 1990; 31: 964-7.
9. Carlson N, Lechago J, Richter J, et al. Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. Am J Gastroenterol 2002; 97: 1340-5.
10. Gerson LB, Boparai V, Ullah N, Triadafiolpoulus G. Esophageal and gastric pH profiles in patients with gastroesophageal reflux disease and Barrett's esophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 2004; 20: 637-43.
11. Niemantsverdriet E, Timmer R, Breumelhof R, Smout AJPM. The roles of excessive gastroesophageal reflux, disordered esophageal motility and decreased mucosal sensitivity in the pathogenesis of Barrett's esophagus. Eur J Gastroenterol Hepatol 1997; 9: 515-9.
12. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in Barrett's esophagus. Am J Gastroenterol 1994; 89: 989-91.
13. Ouata-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998; 93: 711-6.
14. Fass R, Sampliner RE, Malagon IB, et al. Failure of esophageal acid control in candidates for Barrett's esophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000; 14: 597-602.
15. Yeh RW, Gerson LB, Triadafilopoulos G. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus. Dis Esophagus 2003; 16: 193-8.
16. Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44: 700-5.
17. Klinkenberg-Knol EC, Meuwissen SGM. Combined gastric and esophageal 24-hour pH monitoring and esophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment Pharmacol Ther 1990; 4: 485-95.
18. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 582-5.
19. Basu KK, Bale R, West K, de Caestecker JS. Persistent acid reflux and symptoms in patients with Barrett's esophagus on proton-pump inhibitor therapy. Eur J Gastroenterol Hepatol 2002; 14: 1187-92.
20. Ortiz A, Martinez de Haro LF, Parilla P, et al. 24 hour pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's esophagus undergoing treatment with proton pump inhibitors. Br J Surg 1996; 83: 274-8.
21. Sarela A, Hick D, Verbeke C, et al. Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. Arch Surg 2004; 139: 547-51.
22. Leite LP, Johnson BT, Just RJ, Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996; 91: 1527-31.
23. Fouad YM, Katz PO, Castell DO. Esophageal motility defects associated with nocturnal gastro-esophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1999; 13: 1467-71.
24. Fass R, Hell RW, Garewal HS, et al. Correlation of esophageal acid exposure with Barrett's esophagus length. Gut 2001; 48: 310-3.
25. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. J Clin Invest 1996; 98: 2120-8.
26. Ouata-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-35.
27. Gore S, Healey CJ, Sutton R, et al. Regression of columnar lined (Barrett's) esophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7: 623-8.
28. Peters FTM, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's esophagus during omeprazole treatment: a randomized double blind study. Gut 1999; 45: 489-94.
29. Cooper BT, Neumann CS, Cox M, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's esophagus. Aliment Pharmacol Ther 1998; 12: 893-7.
30. Wilkinson S, Biddlestone L, Gore S, Shepherd N. Regression of columnar-lined (Barrett's) esophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999; 13: 1205-9.
31. Srinivasan R, Katz P, Ramakrishnan A, Castell D. Effect of maximal acid reflux control on Barrett's esophagus. Am J Gastroenterol 1999; 94: 260.
32. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago workshop. Gastroenterology 2004; 127: 310-30.
33. El-Serag H, Aguirre T, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877-83.